Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Inhibitors

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search
Image of 2D Structure
Search for synonyms (with exact matching search term)

Search term:

Results 1 - 10 of 250 > >>
EC Number Inhibitors Commentary Structure
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(-)-6-(3-(3-cyclopropyl-3-((1R,2R)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1H)-quinolinone IC50: 0.0001 mM, PDE3A; IC50: 0.00028 mM, PDE3B Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(2R,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol IC50: 0.0043 mM, PDE2 Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(2S,3R)-3-(7-amino-3H-imidazo[4,5-b]pyridin-3-yl)nonan-2-ol - Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(2Z)-9,10-dimethoxy-3-methyl-2-[(2,4,6-trimethylphenyl)imino]-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one IC50: 0.000006 mM, PDE3; IC50: 0.0012 mM, PDE2; IC50: 0.015 mM, PDE1 Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(6aS,9aR)-3-benzyl-2-(biphenyl-4-ylmethyl)-5-methyl-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one comparison of inhibitory effect on several recombinant human PDE isoforms. Effective PDE1 inhibitor in cellular context Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate time-dependent and irreversible inactivation of PDE3A Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)-phenyl)propyl)-5-(4-(trifluoromethyl)-1H-imidazol-1-yl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide - Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.17(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)-phenyl)propyl)-6-methyl-5-(4-methyl-1H-1,2,3-triazol-1-yl)-pyrazolo[1,5-a]pyrimidine-3-carboxamide - Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.171-(2-chlorophenyl)-4-methyl-8-[(morpholin-4-yl)methyl][1,2,4]triazolo[4,3-a]quinoxaline compound shows good combined potency, acceptable brain uptake and high selectivity for both PDE2 and PDE10 enzymes. In microdosing experiment in rats, the compound shows preferential distribution in brain areas Go to the Ligand Summary Page
Show all pathways known for 3.1.4.17Display the word mapDisplay the reaction diagram Show all sequences 3.1.4.171-(2-methylbenzyl)-3-propyl-3,7-dihydro-1H-purine-2,6-dione - Go to the Ligand Summary Page
Results 1 - 10 of 250 > >>